

ERRATUM

VOLUME 79 ISSUE 3 - MAY/JUN 2013

Brazilian academy of rhinology position paper on topical intranasal therapy

João Ferreira de Mello Júnior • Olavo de Godoy Mion • Nilvano Alves de Andrade • Wilma Terezinha Anselmo-Lima • Aldo Eden Cassol Stamm • Washington Luiz de Cerqueira Almeida • Pedro Oliveira Cavalcante Filho • Jair de Carvalho e Castro • Francini Grecco de Melo Padua • Fabrizio Ricci Romano • Rodrigo de Paulo Santos • Renato Roitmann • Richard Louis Voegels • Roberto Campos Meirelles • Leonardo Conrado Barbosa Sá • Moacyr Tabasnik Moacyr • Marco Cesar Jorge dos Santos • Roberto Eustáquio Santos Guimarães

On the lines corresponding to the fluticasone propionate and furoate, the data concerning age and dose are the following:

Table 1. General characteristics of intranasal steroid formulations, age from which it can be used in allergic rhinitis and the corresponding doses for children and adults.

Name	Formulation	Minimum age	Dose per spray mcg*/nostril	Maximum dose/ children mcg/day	Dose/adult mcg/day	Maximum dose for rhinitis and polyps ** mcg/day
Triamcinolone acetonide	Isotonic	4 years	55	110	220	220
Budesonide	Isotonic	6 years	32, 50, 64, 100	100	200	400
Ciclesonide	Hypotonic	6 years	50	100	200	400
Beclomethasone dipropionate	Isotonic	6 years	50	100	200	400
Mometasone furoate	Isotonic	2 years	50	100	200	400
Fluticasone propionate	Isotonic	4 years	50	100	200	400
Fluticasone furoate	Isotonic	2 years	27.5	55	110	220

* mcg = micrograms. Source: Medications' inserts. ** To the present time there is no standardized dose for nasal polyps, only clinical trials, usually with the maximum drug dose³.